Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE PlatformÂŽ (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Companyâs approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concertâs pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.
Source
